Power, potential, and pitfalls in global health academic partnerships: review and reflections on an approach in Nepal.

Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001-2015.

Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study.

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome.

Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.

Jennifer Chen, MD

Biotransformation of furosemide in kidney transplant patients.

The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis.

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Therapeutic Targets in Sepsis: Past, Present, and Future.

Race and renal impairment in heart failure: mortality in blacks versus whites.

Achalasia Quality Indicator Adherence.

A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy.

THE GENETIC BASIS OF DEVELOPMENTAL STABILITY IN APIS MELLIFERA: HETEROZYGOSITY VERSUS GENIC BALANCE.

JAGS Editorial by Dr. Eric Widera Explores Industry-Influenced Workgroup's Proposal to Redefine Alzheimer's Criteria, Prompting Reflection on the Decision-Making Process in Disease Definition

Eric Widera, MD published an editorial in JAGS describing how a workgroup dominated by industry wants to redefine Alzheimer's as an abnormal accumulation of amyloid, regardless of current or future cognitive function. Dr. Widera raises a rarely asked question based on this new definition: "Who gets to decide how to redefine a disease? ".